Cohen David E 4

What Happened
David E. Cohen, a director of Evommune, sold two blocks of common stock on 2026-06-02 and received a derivative award the same day. He disposed of 5,456 shares at a weighted-average price of $20.21 for $110,266 and 600 shares at a weighted-average price of $21.38 for $12,828 (aggregate proceeds ~$123,094). He was also granted a 15,673-share derivative award (reported at $0.00), described in the filing as subject to vesting conditions.

Key Details

• Transaction date: 2026-06-02; Form 4 filed 2026-06-03 (timely filing).
• Sales: 5,456 shares at $20.21 (weighted avg; prices ranged $20.00–$20.99 per footnote) = $110,266; 600 shares at $21.38 (weighted avg; prices ranged $21.06–$21.75 per footnote) = $12,828.
• Award: 15,673-share derivative award reported at $0.00 (no cash paid). Footnote F4: award vests at the earlier of the first anniversary of the grant date or the issuer’s next annual meeting, subject to continuous service.
• Footnote F1: the sales were made pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026 (pre-arranged plan).
• Shares owned after the transactions: not specified in the provided excerpt — see the full Form 4 for post-transaction holdings.

Context
Sales executed under a Rule 10b5-1 plan are pre-planned and are commonly viewed as routine liquidity events rather than fresh statements of insider sentiment. The derivative award appears to be an equity grant (vesting conditions apply); the filing does not indicate a cashless exercise or immediate sale of award shares. For full details (exact post-transaction holdings and any additional clauses), consult the complete Form 4 (Accession: 0001347383-26-000003).